SLX4
Basic information
Region (hg38): 16:3581181-3611606
Previous symbols: [ "BTBD12" ]
Links
Phenotypes
GenCC
Source:
- Fanconi anemia complementation group P (Definitive), mode of inheritance: AR
- Fanconi anemia (Supportive), mode of inheritance: AR
- Fanconi anemia complementation group P (Strong), mode of inheritance: AR
- familial ovarian cancer (No Known Disease Relationship), mode of inheritance: AD
- hereditary breast carcinoma (Refuted Evidence), mode of inheritance: AD
- Fanconi anemia complementation group P (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Fanconi anemia, complementation group P | AR | Allergy/Immunology/Infectious; Cardiovascular; Hematologic; Oncologic | Specific treatments can help manifestations (eg, oral androgens for blood counts; G-CSF for neutrophil count); HSCT can be curative, but solid tumor risk may remain; Surveillance for complications such as bone marrow failure is recommended; Fanconi anemia can involve congenital cardiac (and other) anomalies, and awareness may allow early management | Audiologic/Otolaryngologic; Allergy/Immunology/Infectious; Cardiovascular; Dermatologic; Gastrointestinal; Hematologic; Musculoskeletal; Neurologic; Oncologic; Ophthalmologic; Renal | 21240275; 21240277; 20301575 |
ClinVar
This is a list of variants' phenotypes submitted to
- Fanconi anemia (65 variants)
- not provided (4 variants)
- Fanconi anemia complementation group P (3 variants)
- Fanconi anemia complementation group A (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SLX4 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 17 | 512 | 14 | 543 | ||
missense | 1079 | 26 | 13 | 1118 | ||
nonsense | 29 | 12 | 44 | |||
start loss | 0 | |||||
frameshift | 41 | 13 | 55 | |||
inframe indel | 31 | 32 | ||||
splice donor/acceptor (+/-2bp) | 11 | 11 | ||||
splice region | 27 | 19 | 1 | 47 | ||
non coding | 45 | 91 | 44 | 180 | ||
Total | 70 | 36 | 1176 | 630 | 71 |
Highest pathogenic variant AF is 0.0000197
Variants in SLX4
This is a list of pathogenic ClinVar variants found in the SLX4 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-3581192-C-G | Fanconi anemia complementation group P | Uncertain significance (Jan 13, 2018) | ||
16-3581247-C-T | Fanconi anemia complementation group P | Benign (Jan 12, 2018) | ||
16-3581295-C-T | Fanconi anemia complementation group P | Uncertain significance (Jan 12, 2018) | ||
16-3581301-T-C | Fanconi anemia complementation group P | Likely benign (Jan 13, 2018) | ||
16-3581307-T-C | Fanconi anemia complementation group P | Likely benign (Jan 13, 2018) | ||
16-3581320-T-C | Fanconi anemia complementation group P | Benign (Jan 12, 2018) | ||
16-3581338-T-C | Fanconi anemia complementation group P | Benign (Jan 12, 2018) | ||
16-3581358-G-A | Fanconi anemia complementation group P | Benign (Jan 12, 2018) | ||
16-3581385-G-A | Fanconi anemia complementation group P | Uncertain significance (Jan 13, 2018) | ||
16-3581398-T-C | Fanconi anemia complementation group P | Uncertain significance (Jan 13, 2018) | ||
16-3581455-G-A | Fanconi anemia complementation group P | Uncertain significance (Jan 12, 2018) | ||
16-3581460-G-A | Fanconi anemia complementation group P | Uncertain significance (Jan 13, 2018) | ||
16-3581471-T-C | Fanconi anemia complementation group P | Uncertain significance (Jan 12, 2018) | ||
16-3581531-C-G | Fanconi anemia complementation group P | Uncertain significance (Jan 12, 2018) | ||
16-3581535-C-T | Fanconi anemia complementation group P | Benign (Jan 13, 2018) | ||
16-3581621-A-G | Fanconi anemia complementation group P | Benign (Jan 13, 2018) | ||
16-3581684-A-G | Fanconi anemia complementation group P | Likely benign (Jan 13, 2018) | ||
16-3581687-C-T | Fanconi anemia complementation group P | Benign (Jan 12, 2018) | ||
16-3581690-T-C | Fanconi anemia complementation group P | Uncertain significance (Jan 13, 2018) | ||
16-3581764-C-T | Fanconi anemia complementation group P | Uncertain significance (Jan 13, 2018) | ||
16-3581787-G-A | Fanconi anemia complementation group P | Benign (Jan 12, 2018) | ||
16-3581849-C-A | Fanconi anemia complementation group P | Uncertain significance (Jan 13, 2018) | ||
16-3581873-T-A | Fanconi anemia complementation group P | Uncertain significance (Jan 13, 2018) | ||
16-3581968-G-A | Fanconi anemia complementation group P | Uncertain significance (Jan 13, 2018) | ||
16-3582031-C-T | Fanconi anemia complementation group P | Uncertain significance (Jan 13, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SLX4 | protein_coding | protein_coding | ENST00000294008 | 14 | 30418 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.57e-22 | 0.846 | 125591 | 0 | 157 | 125748 | 0.000624 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -1.88 | 1224 | 1.05e+3 | 1.16 | 0.0000702 | 11861 |
Missense in Polyphen | 296 | 270.99 | 1.0923 | 3358 | ||
Synonymous | -4.09 | 577 | 465 | 1.24 | 0.0000356 | 3821 |
Loss of Function | 2.41 | 45 | 66.2 | 0.680 | 0.00000369 | 767 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000651 | 0.000650 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00132 | 0.00131 |
Finnish | 0.000372 | 0.000370 |
European (Non-Finnish) | 0.000709 | 0.000695 |
Middle Eastern | 0.00132 | 0.00131 |
South Asian | 0.000852 | 0.000817 |
Other | 0.000326 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage. Component of the SLX1-SLX4 structure-specific endonuclease that resolves DNA secondary structures generated during DNA repair and recombination. Has endonuclease activity towards branched DNA substrates, introducing single-strand cuts in duplex DNA close to junctions with ss-DNA. Has a preference for 5'-flap structures, and promotes symmetrical cleavage of static and migrating Holliday junctions (HJs). Resolves HJs by generating two pairs of ligatable, nicked duplex products. Interacts with the structure- specific ERCC4-ERCC1 endonuclease and promotes the cleavage of bubble structures. Interacts with the structure-specific MUS81- EME1 endonuclease and promotes the cleavage of 3'-flap and replication fork-like structures. SLX4 is required for recovery from alkylation-induced DNA damage and is involved in the resolution of DNA double-strand breaks. {ECO:0000269|PubMed:19595721, ECO:0000269|PubMed:19595722, ECO:0000269|PubMed:19596235, ECO:0000269|PubMed:19596236}.;
- Disease
- DISEASE: Fanconi anemia complementation group P (FANCP) [MIM:613951]: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. Some individuals affected by Fanconi anemia of complementation group P have skeletal anomalies. {ECO:0000269|PubMed:21240275, ECO:0000269|PubMed:21240277}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Fanconi anemia pathway - Homo sapiens (human);HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA);Fanconi Anemia Pathway;DNA Repair;DNA Double-Strand Break Repair;Homology Directed Repair;Resolution of D-loop Structures through Holliday Junction Intermediates;Resolution of D-Loop Structures;HDR through Homologous Recombination (HRR)
(Consensus)
Intolerance Scores
- loftool
- rvis_EVS
- 1.17
- rvis_percentile_EVS
- 92.73
Haploinsufficiency Scores
- pHI
- 0.0621
- hipred
- Y
- hipred_score
- 0.568
- ghis
- 0.547
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.114
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | High |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Slx4
- Phenotype
- growth/size/body region phenotype; endocrine/exocrine gland phenotype; craniofacial phenotype; cellular phenotype; homeostasis/metabolism phenotype; immune system phenotype; skeleton phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; vision/eye phenotype;
Zebrafish Information Network
- Gene name
- slx4
- Affected structure
- intrahepatic bile duct
- Phenotype tag
- abnormal
- Phenotype quality
- absent
Gene ontology
- Biological process
- meiotic DNA double-strand break processing;resolution of meiotic recombination intermediates;double-strand break repair via homologous recombination;DNA replication;DNA repair;nucleotide-excision repair;DNA double-strand break processing involved in repair via single-strand annealing;interstrand cross-link repair;positive regulation of catalytic activity;telomeric D-loop disassembly;response to intra-S DNA damage checkpoint signaling;t-circle formation;negative regulation of telomere maintenance via telomere lengthening;positive regulation of t-circle formation
- Cellular component
- chromosome, telomeric region;nuclear chromosome, telomeric region;nuclear chromatin;nucleoplasm;cytosol;cell junction;Slx1-Slx4 complex;Holliday junction resolvase complex;ERCC4-ERCC1 complex
- Molecular function
- endodeoxyribonuclease activity;protein binding;enzyme activator activity;crossover junction endodeoxyribonuclease activity;5'-flap endonuclease activity;3'-flap endonuclease activity